Related Experiment Video
Updated: May 27, 2026
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
Novel GLP-1 receptor agonists for diabetes
1Baylor College of Medicine, Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, One Baylor Plaza-BCM620, Houston, TX 77030, USA. agarber@bcm.edu
Expert Opinion on Investigational Drugs
|November 25, 2011
Summary
Glucagon-like peptide-1 (GLP-1) receptor agonists offer significant benefits for type 2 diabetes mellitus (T2DM) management, aiding in weight loss and glucose control. These agents represent a major therapeutic advancement for T2DM patients.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Glucagon-like peptide-1 (GLP-1) receptor agonists are established treatments for type 2 diabetes mellitus (T2DM).
- Development has shifted towards longer-acting formulations, including once-daily and once-weekly options, improving patient convenience.
Purpose of the Study:
- To review the mechanism of action of GLP-1 receptor agonists.
- To discuss the clinical development and therapeutic applications of various agents in this class for T2DM.
Main Methods:
- Discussion of GLP-1's role in glycemic control.
- Overview of the clinical development of five GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, taspoglutide) since 2005.
- Review of their mechanisms, efficacy (glycemic control, weight loss), and tolerability.
Main Results:
- GLP-1 receptor agonists demonstrate efficacy in improving glucose homeostasis.
- These agents are associated with clinically meaningful weight loss.
- The review covers agents like exenatide, liraglutide, lixisenatide, albiglutide, and taspoglutide.
Conclusions:
- GLP-1 receptor agonists provide significant clinical benefits for T2DM patients, including weight loss and improved glucose control.
- They offer advantages over traditional therapies like sulfonylureas and DPP-4 inhibitors.
- These agents are poised to become a primary therapeutic choice for managing T2DM.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...